Your browser doesn't support javascript.
loading
Role of immunotherapy in castration-resistant prostate cancer (CRPC).
Suárez, Cristina; Morales-Barrera, Rafael; Ramos, Victor; Núñez, Isaac; Valverde, Claudia; Planas, Jacques; Morote, Juan; Maldonado, Xavier; Carles, Joan.
Afiliação
  • Suárez C; Genitourinary, Sarcoma, and Central Nervous System Tumor Program, Medical Oncology Department, Universitat Autònoma Barcelona, Barcelona, Spain.
BJU Int ; 113(3): 367-75, 2014 Mar.
Article em En | MEDLINE | ID: mdl-23650874
ABSTRACT
Initial therapy for metastatic prostate cancer consists of androgenic suppression. However, this is only a palliative treatment with an effective duration that usually lasts 12-24 months. Historically, castration-resistant prostate cancer (CRPC) had been considered a chemoresistant tumour. In 2004, docetaxel received USA Food and Drug Administration approval as a first-line treatment for metastatic prostate cancer, after two independent phase III trials showed an increased survival benefit. Recently, five new drugs have shown increased survival in CRPC sipuleucel-T (assymptomatic or minimally symptomatic), abiraterone acetate (before and after docetaxel), cabazitaxel (after docetaxel), MDV3100 (after docetaxel) and radium-223 (not suitable for docetaxel or after docetaxel). The identification of antigens in normal prostate tissue or prostate cancer that are recognised by immune effectors cells has resulted in several new studies based on immunotherapy. Prostate cancer disease provides a test system to determine the efficacy of vaccines for different reasons. This cancer is a tumour that grows relatively slowly. Recurrence is often diagnosed early (with many patients presenting only with biochemical progression), there is a biological marker that can predict prognosis and outcome (PSA doubling time), various specific antigens have been identified and characterised, and vaccines can be used with a good safety profile combined with anti-androgen therapy, chemotherapy, or radiotherapy. Here we provide a review of the main important immune treatments in CRPC.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Anticâncer / Neoplasias de Próstata Resistentes à Castração / Imunoterapia / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Revista: BJU Int Assunto da revista: UROLOGIA Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Anticâncer / Neoplasias de Próstata Resistentes à Castração / Imunoterapia / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Revista: BJU Int Assunto da revista: UROLOGIA Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Espanha